4-(2,4-difluorophenyl)-4-oxobut-2-enoic acid | 83844-25-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2,4-difluorophenyl)-4-oxobut-2-enoic acid
• CAS: 83844-25-1
• 化学式: C₁₀H₆F₂O₃
• mdl: MFCD20402321
• 分子量: 212.15
• InChiKey: GYTCEHNGUPAFMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Erythropoietin Expression Promoter
  申请人：TOHOKU UNIVERSITY

  公开号：US20150353489A1

  公开（公告）日：2015-12-10

  The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R 3 is OH.

  本发明提供了一种促进红细胞生成素表达的药剂，可以取消红细胞生成素产生的抑制或促进红细胞生成素的产生，并且包括用于贫血的治疗或预防药物、改善肝功能的药剂、改善缺血性损伤的药剂、肾脏保护剂和胰岛素分泌促进剂，其中包括红细胞生成素表达增强剂。本发明的红细胞生成素表达增强剂包括从以下一般式（I）、（II）和（III）所代表的化合物组中选择的一个或多个化合物及其在R3为OH时的药用盐。
• Agent for Preventing or Ameliorating Hearing Impairment
  申请人：Tohoku University

  公开号：US20190224165A1

  公开（公告）日：2019-07-25

  It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I 0 ), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R 3 is OH are used as an agent for preventing or improving hearing loss.

  这是为预防或改善听力损失提供一种药剂，包括一种低分子化合物作为活性成分，可以相对容易和廉价地生产。当R3为OH时，以下化合物组成的化合物群中选择一个或多个化合物，以及这些化合物的药用盐，被用作预防或改善听力损失的药剂。
• ERYTHROPOIETIN EXPRESSION PROMOTER
  申请人：Tohoku University

  公开号：EP2923700A1

  公开（公告）日：2015-09-30

  The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

  本发明提供了一种可消除对促红细胞生成素生成的抑制或促进促红细胞生成素生成的促红细胞生成素表达剂，以及包含该促红细胞生成素表达剂的贫血治疗或预防药物、肝功能改善剂、缺血性损伤改善剂、肾保护剂和胰岛素分泌剂。本发明的红细胞生成素表达促进剂包括一种或多种选自由下列通式（I）、（II）和（III）所代表的化合物组成的化合物及其药学上可接受的盐，当 R3 为 OH 时。
• Erythropoietin expression promoter
  申请人：TOHOKU UNIVERSITY

  公开号：US10004718B2

  公开（公告）日：2018-06-26

  The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R3 is OH.

  本发明提供了一种可消除对促红细胞生成素生成的抑制或促进促红细胞生成素生成的促红细胞生成素表达剂，以及包含该促红细胞生成素表达剂的贫血治疗或预防药物、肝功能改善剂、缺血性损伤改善剂、肾保护剂和胰岛素分泌剂。本发明的红细胞生成素表达促进剂包括一种或多种选自由下列通式（I）、（II）和（III）所代表的化合物组成的化合物及其药学上可接受的盐，当 R3 为 OH 时。
• Therapeutic agent for amyotrophic disorders
  申请人：TOHOKU UNIVERSITY

  公开号：US10869858B2

  公开（公告）日：2020-12-22

  It is an object of the present invention to provide a novel therapeutic agent and method for treating amyotrophic diseases, and more specifically a therapeutic agent and method for treating neurogenic amyotrophic disorders such as amyotrophic lateral sclerosis (ALS) and myogenic amyotrophic disorders such as sarcopenia or disuse muscle atrophy. Provided is a therapeutic agent for amyotrophic diseases that comprises one or more compounds selected from the group consisting of compounds represented by the formula (I), the formula (II) and the formula (III), and pharmaceutically acceptable salts of the compounds when R3 represents OH.

  本发明的目的是提供一种治疗肌萎缩疾病的新型治疗剂和方法，更具体地说，是一种治疗神经源性肌萎缩疾病（如肌萎缩性脊髓侧索硬化症（ALS））和肌源性肌萎缩疾病（如肌肉疏松症或废用性肌肉萎缩症）的治疗剂和方法。本发明提供了一种肌萎缩性疾病的治疗剂，该治疗剂包含一种或多种选自由式（I）、式（II）和式（III）所代表的化合物组成的组的化合物，以及当R3代表OH时该化合物的药学上可接受的盐。